Sandra Panem
Vermogen: - $ op 31-05-2026
Vermogen: - $ op 31-05-2026
Sandra Panem is the founder of Neuronetworks Fund, serving as President since 2014.
Current jobs include Director at GQ Life Sciences, Inc., Independent Director at BioLineRx Ltd. since 2014, and Managing Partner at Cross Atlantic Partners, Inc. since 2010.
Former jobs include Director at Bioject Medical Technologies, Inc. from 2001 to 2006, Director at Martek Biosciences Corp.
from 1995 to 2006, Director at IBAH, Inc., Director at Confluent Surgical, Inc., Director at Gene-IT, Inc., Director at Molecular Informatics, Inc., Director at Labcyte, Inc., Director at MDX Medical, Inc., Independent Director at Acorda Therapeutics, Inc. from 1998 to 2024, Vice President at Salomon Brothers Asset Management, Inc., Vice President & Portfolio Manager at Oppenheimer & Co., Inc., Principal at The Brookings Institution, Assistant Professor at The University of Chicago, and President at Vector Asset Management, Inc. from 1994 to 1999.
Education includes a doctorate from The University of Chicago in 1970 and an undergraduate degree from The University of Chicago in 1966.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
BIOLINERX LTD. -.--% | 18-03-2026 | 0 ( -.--% ) | - $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| BIOLINERX LTD. | Directeur/Bestuurslid | 24-02-2014 |
GQ Life Sciences, Inc.
GQ Life Sciences, Inc. Packaged SoftwareTechnology Services Provides software solutions to life science research organizations | Directeur/Bestuurslid | - |
Cross Atlantic Partners, Inc.
Cross Atlantic Partners, Inc. Investment ManagersFinance Cross Atlantic focuses only on US-based healthcare opportunities, especially in drug discovery, devices and services. They place emphasis on oncology, neurological diseases and infectious diseases. They look for companies seeking to develop more effective, less expensive products or services which reduce the need for surgery or hospitalization and provide higher quality care at a lower cost. Cross Atlantic invests in companies beyond the start-up stage. They seek companies whose innovative products show clear competitive advantages. Such products should be based on proprietary technology or specialized service expertise and should meet significant market needs. In-depth review of patent portfolios is a standard part of their due diligence. The firm expects at least a 3X return of capital with an average holding period of 4 years. Exit strategies may include the sale of securities through IPOs, secondary public and private offerings, sales in connection with strategic alliance/corporate partnering transactions or merger and acquisition transactions. | Private Equity Investor | 01-01-2000 |
Neuronetworks Fund
Neuronetworks Fund Investment ManagersFinance Operates as a venture capital fund | Oprichter | 01-12-2014 |
| Bedrijven | Functie | Einde |
|---|---|---|
| ACORDA THERAPEUTICS, INC. | Directeur/Bestuurslid | 21-08-2024 |
Gene-IT, Inc.
Gene-IT, Inc. Packaged SoftwareTechnology Services Provides software solutions to life-science research organizations | Directeur/Bestuurslid | 25-09-2007 |
Martek Biosciences Corp.
Martek Biosciences Corp. BiotechnologyHealth Technology Develops, manufactures and sells products derived from microalgae | Directeur/Bestuurslid | 31-10-2006 |
| BIOJECT MEDICAL TECHNOLOGIES INC. | Directeur/Bestuurslid | 11-08-2006 |
Vector Asset Management, Inc.
Vector Asset Management, Inc. Investment ManagersFinance Vector Asset Management invests in later-stage private and public companies in the life sciences and healthcare industries. Specific areas of interest include: biotechnology, pharmaceuticals, medical devices, diagnostics, plant and animal sciences, healthcare services, healthcare information technology and consumer applications of emerging healthcare technologies. They focus on companies that are raising capital in the private markets prior to the point at which they can access the public markets or execute an alternative exit strategy. Vector looks for companies ready to move from development stage to commercially viable operating entities in a relatively short time. The firm also participates in equity transactions involving securities of small- to mid-cap public companies in the life sciences and healthcare area. Most of Vector's investments are negotiated directly with company management. Vector is an active investor and generally leads or co-leads their investments. They usually serve on the Board of Directors of their portfolio companies. Investments range from $5 million to $15 million with an investment horizon of one to three years. | President | 01-01-1999 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 18 |
|---|---|
Bioject Medical Technologies, Inc.
Bioject Medical Technologies, Inc. Medical SpecialtiesHealth Technology Develops and manufactures needle-free injection therapy systems | Health Technology |
Martek Biosciences Corp.
Martek Biosciences Corp. BiotechnologyHealth Technology Develops, manufactures and sells products derived from microalgae | Health Technology |
IBAH, Inc.
IBAH, Inc. Miscellaneous Commercial ServicesCommercial Services Provides product development services for pharmaceutical businesses | Commercial Services |
Salomon Brothers Asset Management, Inc.
Salomon Brothers Asset Management, Inc. Investment ManagersFinance Manages assets. | Finance |
Oppenheimer & Co., Inc.
Oppenheimer & Co., Inc. Investment ManagersFinance Provides wealth and asset management, brokerage & investment banking services | Finance |
Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops neurology therapies | Health Technology |
Confluent Surgical, Inc.
Confluent Surgical, Inc. Medical SpecialtiesHealth Technology Designs and develops medical devices | Health Technology |
Gene-IT, Inc.
Gene-IT, Inc. Packaged SoftwareTechnology Services Provides software solutions to life-science research organizations | Technology Services |
GQ Life Sciences, Inc.
GQ Life Sciences, Inc. Packaged SoftwareTechnology Services Provides software solutions to life science research organizations | Technology Services |
The Brookings Institution
The Brookings Institution Miscellaneous Commercial ServicesCommercial Services Provides research and policy solutions | Commercial Services |
Molecular Informatics, Inc.
Molecular Informatics, Inc. Packaged SoftwareTechnology Services Develops bioinformatics software | Technology Services |
The University of Chicago
The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cross Atlantic Partners, Inc.
Cross Atlantic Partners, Inc. Investment ManagersFinance Cross Atlantic focuses only on US-based healthcare opportunities, especially in drug discovery, devices and services. They place emphasis on oncology, neurological diseases and infectious diseases. They look for companies seeking to develop more effective, less expensive products or services which reduce the need for surgery or hospitalization and provide higher quality care at a lower cost. Cross Atlantic invests in companies beyond the start-up stage. They seek companies whose innovative products show clear competitive advantages. Such products should be based on proprietary technology or specialized service expertise and should meet significant market needs. In-depth review of patent portfolios is a standard part of their due diligence. The firm expects at least a 3X return of capital with an average holding period of 4 years. Exit strategies may include the sale of securities through IPOs, secondary public and private offerings, sales in connection with strategic alliance/corporate partnering transactions or merger and acquisition transactions. | Finance |
Labcyte, Inc.
Labcyte, Inc. Medical/Nursing ServicesHealth Services Operates as a biotechnology tools company that manufactures and markets echo liquid handling systems | Health Services |
BioLineRx Ltd.
BioLineRx Ltd. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company which develops and commercializes cell transplantation products | Health Technology |
Vector Asset Management, Inc.
Vector Asset Management, Inc. Investment ManagersFinance Vector Asset Management invests in later-stage private and public companies in the life sciences and healthcare industries. Specific areas of interest include: biotechnology, pharmaceuticals, medical devices, diagnostics, plant and animal sciences, healthcare services, healthcare information technology and consumer applications of emerging healthcare technologies. They focus on companies that are raising capital in the private markets prior to the point at which they can access the public markets or execute an alternative exit strategy. Vector looks for companies ready to move from development stage to commercially viable operating entities in a relatively short time. The firm also participates in equity transactions involving securities of small- to mid-cap public companies in the life sciences and healthcare area. Most of Vector's investments are negotiated directly with company management. Vector is an active investor and generally leads or co-leads their investments. They usually serve on the Board of Directors of their portfolio companies. Investments range from $5 million to $15 million with an investment horizon of one to three years. | Finance |
MDX Medical, Inc
MDX Medical, Inc Information Technology ServicesTechnology Services Provides healthcare shopping and navigation tool services | Technology Services |
Neuronetworks Fund
Neuronetworks Fund Investment ManagersFinance Operates as a venture capital fund | Finance |
Kies jouw editie
Alle financiële informatie op nationaal niveau